CVX Vs XOM Stock, Which Energy Play Is Best?
Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…
Buy
56
ALHC Quote, Financials, Valuation and Earnings
Last price:
$15.51
Seasonality move
:
22.79%
Day range:
$15.17 - $15.77
52-week range:
$6.66 - $21.06
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.01x
P/B ratio:
28.76x
Volume:
2.9M
Avg. volume:
3.8M
1-year change:
131.86%
Market cap:
$3.1B
Revenue:
$2.7B
EPS (TTM):
-$0.48
Analysts' Opinion
-
Consensus RatingAlignment Healthcare has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $18.22, Alignment Healthcare has an estimated upside of 15.92% from its current price of $15.72.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $9.00 representing 42.75% downside risk from its current price of $15.72.
Fair Value
-
According to the consensus of 9 analysts, Alignment Healthcare has 15.92% upside to fair value with a price target of $18.22 per share.
ALHC vs. S&P 500
-
Over the past 5 trading days, Alignment Healthcare has underperformed the S&P 500 by -9.86% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Alignment Healthcare does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Alignment Healthcare has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Alignment Healthcare reported revenues of $926.9M.
Earnings Growth
-
Alignment Healthcare has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Alignment Healthcare reported earnings per share of -$0.05.
Enterprise value:
3B
EV / Invested capital:
6.85x
Price / LTM sales:
1.01x
EV / EBIT:
--
EV / Revenue:
0.98x
PEG ratio (5yr expected):
-0.98x
EV / Free cash flow:
154.82x
Price / Operating cash flow:
158.18x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$347.3M
Return On Assets:
-12.18%
Net Income Margin (TTM):
-3.02%
Return On Equity:
-77.81%
Return On Invested Capital:
-25.02%
Operating Margin:
-0.58%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $1.5B | $2B | $3B | $628.6M | $926.9M | |
| Gross Profit | $185.4M | $213.6M | $347.3M | $55.4M | $106M | |
| Operating Income | -$124.7M | -$136.4M | -$65.8M | -$41.1M | -$5.4M | |
| EBITDA | -$108.5M | -$113M | -$40.1M | -$35.1M | $2.2M | |
| Diluted EPS | -$0.79 | -$0.84 | -$0.48 | -$0.25 | -$0.05 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $604.6M | $566.2M | $670.9M | $520.6M | $774.5M | |
| Total Assets | $679.3M | $646.6M | $761.8M | $633.2M | $895.6M | |
| Current Liabilities | $169.8M | $195M | $374.2M | $330.7M | $457.1M | |
| Total Liabilities | $325.1M | $353.3M | $537.8M | $501.2M | $786.6M | |
| Total Equity | $354.3M | $293.3M | $223.9M | $132M | $109M | |
| Total Debt | $145.7M | $152.3M | $161.1M | $162M | $321.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $51.3M | -$150.5M | $57.6M | -$6.2M | $16.6M | |
| Cash From Investing | -$132.5M | $5.9M | -$7M | $42.7M | -$3.5M | |
| Cash From Financing | $16.6M | -$260K | $156.5M | -$335K | $181K | |
| Free Cash Flow | $25.2M | -$190.4M | $19.1M | -$17.4M | $8.4M | |
ALHC
Sector
Market Cap
$3.1B
$34.5M
Price % of 52-Week High
74.64%
43.57%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.79%
1-Year Price Total Return
131.86%
-42.08%
Beta (5-Year)
--
0.660
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$16.73
200-day SMA
Buy
Level
$12.88
Bollinger Bands (100)
Buy
Level
12.4 - 17.66
Chaikin Money Flow
Buy
Level
21.2M
20-day SMA
Sell
Level
$17.96
Relative Strength Index (RSI14)
Sell
Level
36.57
ADX Line
Sell
Level
30.25
Williams %R
Neutral
Level
-72.449
50-day SMA
Sell
Level
$17.01
MACD (12, 26)
Sell
Level
-0.40
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Sell
Level
-3.3M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.587)
Sell
CA Score
(Annual)
Level (-1.0402)
Buy
Beneish M-Score
(Annual)
Level (-3.2847)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (3.2681)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.
Stock Forecast FAQ
In the current month, ALHC has received 6 Buy ratings 3 Hold ratings, and 0 Sell ratings. The ALHC average analyst price target in the past 3 months is $18.22.
-
Where Will Alignment Healthcare Stock Be In 1 Year?
According to analysts, the consensus estimate is that Alignment Healthcare share price will rise to $18.22 per share over the next 12 months.
-
What Do Analysts Say About Alignment Healthcare?
Analysts are divided on their view about Alignment Healthcare share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Alignment Healthcare is a Sell and believe this share price will drop from its current level to $9.00.
-
What Is Alignment Healthcare's Price Target?
The price target for Alignment Healthcare over the next 1-year time period is forecast to be $18.22 according to 9 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is ALHC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Alignment Healthcare is a Buy. 6 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ALHC?
You can purchase shares of Alignment Healthcare via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Alignment Healthcare shares.
-
What Is The Alignment Healthcare Share Price Today?
Alignment Healthcare was last trading at $15.51 per share. This represents the most recent stock quote for Alignment Healthcare. Yesterday, Alignment Healthcare closed at $15.72 per share.
-
How To Buy Alignment Healthcare Stock Online?
In order to purchase Alignment Healthcare stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is it Safe to Invest in Google With OpenAI Threats?
For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…
Is Broadcom Stock a Millionaire Maker?
Broadcom (Nasdaq: AVGO) stock has gone up more than 64%…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
60
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
60
RGC alert for May 7
Regencell Bioscience Holdings [RGC] is up 22.52% over the past day.
Buy
77
FARO alert for May 7
Faro Technologies [FARO] is down 0% over the past day.
Buy
53
SRPT alert for May 7
Sarepta Therapeutics [SRPT] is down 21.54% over the past day.
